Cladribine

Ocrevus Still Top Therapy for Progressive MS Forms, Report Finds

Ocrevus (ocrelizumab) continues to be the most commonly prescribed therapy for progressive forms of multiple sclerosis (MS), including primary progressive MS (PPMS) and secondary progressive MS (SPMS), according to an analysis from the market intelligence firm Spherix Global Insights. However, other therapies are “gaining traction” among…

Skin Reactions ‘Frequent’ With Mavenclad, Real-world Study Finds

Skin reactions are common amongĀ relapsing-remitting multiple sclerosis (RRMS) patients being treated with oral Mavenclad (cladribine), affecting about one-third of the people evaluated inĀ a real-world study in Germany. These findings suggest the need for careful clinical surveillance to rapidly diagnose and possibly treat skin problems stemming from Mavenclad’s use,…

Slipping Over the Event Horizon Into SPMS

Isn’t it just like me to start my column with a physics analogy that is already confusing? Please stick with me, as all will be revealed. My point is that if a black hole is big enough, you might slip through its event horizon without even noticing. There would…

#AANAM ā€“ Exploring Mavenclad’s Effects on Immune Cells

Editorā€™s note: TheĀ Multiple Sclerosis News TodayĀ team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, held April 17ā€“22. GoĀ hereĀ to read stories from the conference. After starting treatment with the multiple sclerosis (MS) therapy Mavenclad (cladribine), some types of immune cells are more affected…

MS News that Caught My Eye Last Week: Mavenclad and Ocrevus Use Rising in EU, Ampyra Patent Appeal Denied, Exercise and MS Pilot Study

Mavenclad, Ocrevus Use Rising in EU as Injectables and Tysabri Decline, Spherix Reports I’m not surprised at reports that the use of Mavenclad (cladribine) and Ocrevus (ocrelizumab) is increasing in Europe, or that the use of injectable disease-modifying therapies appears to be declining there. Mavenclad and Ocrevus are approved…

MS News that Caught My Eye Last Week: Ozanimod, Achtar Gel, Onset Age Progression Link, Glial Cells Could Differentiate MS Types

In this column, I take a look at more exciting research from the ECTRIMS2019 conference this month. #ECTRIMS2019 ā€“ Ozanimodā€™s ā€˜Key Advantagesā€™ May Lead to New First-line MS Therapy: Interview with Neurologist Jeffrey Cohen This year we’ve seen the approval of two new multiple sclerosis treatments in the United…

#ECTRIMS2019 – Ahead for Mavenclad: Fuller Understanding of What Makes It ‘Unique,’ Serono Exec Says in Interview

Real-world data continues to support the safety and effectiveness ofĀ MavencladĀ (cladribineĀ tablets) in treating multiple sclerosis (MS), and several studies underway will help scientists gain in-depth understanding of how Mavenclad works, its impact on the immune system, and the durability of its benefits, an executive with EMD SeronoĀ said in an…

MS Therapies Among Limited Offerings Through AllianceRx Walgreens Prime

Medications for treating certain rare and chronic conditions, Ā including multiple sclerosis (MS), are now available from the specialty and home delivery pharmacy AllianceRx Walgreens Prime, the company announced. The newly included specialty medications are all limited distribution drugs (LDDs), which means the drug manufacturers have signed agreements giving very…